Actively Recruiting
Study of Botulinum Toxin A BTX-A for Treating Posttraumatic Headache and Exploring Biomarkers to Predict Treatment Success
Led by Danish Headache Center · Updated on 2025-02-21
80
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of botulinum toxin type A BTX-A for treating post-traumatic headache PTH, a common consequence of mild traumatic brain injury. This randomized, placebo-controlled, double-blind study involves 80 participants with persistent PTH. The study aims to explore whether BTX-A can reduce moderate-to-severe headache days and investigate neuroinflammatory biomarkers that might predict treatment response. Participants will be randomly assigned to receive either BTX-A or a saline placebo through 31 subcutaneous injections totaling 155 units of BTX-A, following the PREEMPT protocol. The trial includes a 4-week baseline phase, followed by a single treatment cycle and a 12-week evaluation period to assess changes in headache frequency and severity. The placebo group will receive injections with isotonic saline matching the BTX-A administration schedule. During the study, participants will track headache days and severity, and researchers will collect biomarker samples, including CGRP levels in tear fluid. The primary outcome is the change in moderate-to-severe headache days comparing the baseline phase to the evaluation period. Safety and side effects will be monitored throughout. The total participation duration covers the baseline and evaluation phases over approximately 16 weeks.
CONDITIONS
Brief Title
Safety and Efficacy of Botulinum Toxin A in Patients With Posttraumatic Headache
Research Team
L
Lucia Zavala, MD
H
Henrik Schytz, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here